BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 10-Q: FY2025 Q3 Revenue: USD 81 K

Revenue: As of FY2025 Q3, the actual value is USD 81 K.

EPS: As of FY2025 Q3, the actual value is USD -1.31.

EBIT: As of FY2025 Q3, the actual value is USD -1.001 M.

Segment Revenue

• Product Revenue - Fire Safety: $81,000 for the three and nine months ended September 30, 2025.
• Clinical Trial Supply: $0 for the three and nine months ended September 30, 2025, compared to $10,000 and $43,000 for the same periods in 2024.

Operational Metrics

• Operating Loss: - $992,000 for the three months ended September 30, 2025, compared to - $2,177,000 for the same period in 2024.
• Net Loss: - $988,000 for the three months ended September 30, 2025, compared to - $1,957,000 for the same period in 2024.
• Total Operating Expenses: $1,073,000 for the three months ended September 30, 2025, compared to $2,187,000 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $4,737,000 for the nine months ended September 30, 2025, compared to - $6,634,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $5,523,000 for the nine months ended September 30, 2025, compared to $6,209,000 for the same period in 2024.

Unique Metrics

• Gain on Deconsolidation of Subsidiary: $4,947,000 for the nine months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to focus on fire safety protection and distribution activities following the acquisition of Fitters Sdn. Bhd., anticipating growth in revenues during the fourth quarter of 2025.
• Non-Core Business: The company sold its bio-pharmaceutical asset plogosertib for $300,000, with a potential milestone payment of $170,000.
• Priority: The company is exploring strategic alternatives to continue as a going concern, including raising additional capital through equity financing or strategic transactions.